viivhealthcare.ca

viivhealthcare.com

Inside ViiV Healthcare | ViiV Healthcare

https://www.viivhealthcare.com/inside-viiv-healthcare.aspx

Positive Partnerships initiative launches in Estonia. Read how ViiV Healthcare's Positive Partnerships programme in Estonia is supporting innovative digital health solutions in HIV. Young Britons break down HIV stigma and isolation to be the #GenEndIt. Read what our Global Medical Lead for Paediatrics Dr Katy Hayward thinks about the urgent need to support young people to tackle HIV stigma and fight the epidemic in the UK and around the world. Addressing HIV in Adolescents.

viivhealthcare.com

What we do | ViiV Healthcare

https://www.viivhealthcare.com/what-we-do.aspx

We research and develop new HIV medicines. We improve access to our medicines. We partner with the HIV community. We collaborate to innovate. We research and develop new HIV medicines. We are focused on finding new medicines to improve outcomes for people living with HIV and understanding how best to prevent and treat the disease. We improve access to our medicines. We are committed to playing our part in increasing access to HIV treatment by taking an innovative, responsible and sustainable approach.

viivhealthcare.com

Dolutegravir Expanded Access Program | ViiV Healthcare

https://www.viivhealthcare.com/what-we-do/dolutegravir-expanded-access-program.aspx

Dolutegravir Expanded Access Program. Dolutegravir is an integrase strand transfer inhibitor (INSTI), for use in combination with other anti-retroviral medicinal products for the treatment of HIV infected adults and adolescents above 12 years of age, approved by the Food and Drug Administration in August 2013 and by the European Medicines Agency in January 2014. Who can participate in the dolutegravir EAP (ING114916) or NPP (ING115502)? Have documented raltegravir or elvitegravir resistance. Have any con...

viivhealthcare.com

Media | ViiV Healthcare

https://www.viivhealthcare.com/media.aspx

These press releases are intended for business journalists and analysts/investors. ViiV Healthcare launches phase III programme evaluating a two-drug regimen combining dolutegravir and lamivudine for HIV-1 treatment. ViiV Healthcare launches phase III programme evaluating a two-drug regimen combining dolutegravir and lamivudine for HIV-1 treatment. ARIA study shows superior efficacy of Triumeq for treatment-naïve women living with HIV. ViiV Healthcare announces public tender agreement with Botswana Minis...

viivhealthcare.com

Home | ViiV Healthcare

https://www.viivhealthcare.com/??a=39

ViiV Healthcare launches phase III programme evaluating a two-drug regimen combining dolutegravir and lamivudine for HIV-1 treatment. MEDIA ALERT: ARIA shows superior efficacy of Triumeq for women. ViiV Healthcare presents 48-week data for the phase IIIb ARIA study in treatment-naive women at IAC 2016. Positive Action for Children Collaborathon Grants Announced. Learn more about the four new grants awarded from the first-ever Collaborathon held around the 21st International AIDS Conference.

viivhealthcare.com

Healthcare professionals | ViiV Healthcare

https://www.viivhealthcare.com/healthcare-professionals.aspx

ViiV Healthcare builds partnerships with healthcare professionals (HCPs) by offering expertise and the opportunity to work together on developing new treatments combining it with HCPs scientific and medical insights into patient care. We believe this partnership is fundamental to the progress of medical science and helps meet the needs of patients living with HIV. ViiV Healthcare Clinical Study Register. Dolutegravir Expanded Access Program. US Patient Assistance Programmes.

viivhealthcare.com

Community Partnerships | ViiV Healthcare

https://www.viivhealthcare.com/community-partnerships.aspx

The ViiV Healthcare Effect. Learn about our partners’ projects around the world, currently funded by our Positive Action, Positive Action Southern Initiative, Positive Action for Children Fund and Paediatric Innovation Seed Fund programmes. Positive Action Community Challenge. ViiV Healthcare is announcing its first challenge in the area of HIV and global health, focused on expanding access to health care in rural and other limited resource settings. Positive Action for Adolescents. Addressing gaps in se...

viivhealthcare.com

Careers | ViiV Healthcare

https://www.viivhealthcare.com/careers.aspx

If you are passionate about making a difference to people living with HIV wed love to meet you. A step-by-step guide to our recruitment process and how to set up an email notification of vacancies that match your requirements. Find out about current vacancies in the ViiV Healthcare team. Over 700 ViiV Healthcare staff work in 15 countries around the globe. We employ over 500 people across 16 countries. The number of HIV community organisations we supported in 2012 worldwide.

viivhealthcare.com

Our medicines | ViiV Healthcare

https://www.viivhealthcare.com/our-medicines.aspx

Combination of Integrase inhibitor and (2) Nucleoside reverse transcriptase inhibitors (NRTI). Nucleoside reverse transcriptase inhibitor (NRTI). Nucleoside reverse transcriptase inhibitor (NRTI). Nucleoside reverse transcriptase inhibitor (NRTI). Nucleoside reverse transcriptase inhibitor (NRTI). Nucleoside reverse transcriptase inhibitor (NRTI). Nucleoside reverse transcriptase inhibitor (NRTI). Non-nucleoside reverse transcriptase inhibitor (NNRTI). Report a side effect. Report a side effect.

viivhealthcare.com

About us | ViiV Healthcare

https://www.viivhealthcare.com/about-us.aspx

Our culture and values. We are an independent company combining the HIV expertise of GlaxoSmithKline, Pfizer and Shionogi. Our culture and values. At ViiV Healthcare everyone feels strongly connected to HIV. Over 700 ViiV Healthcare staff work in 15 countries around the globe. Corporate ethics and compliance. We are committed to conducting our business with integrity, in accordance with the highest standards of ethical behaviour.